AxoGen, Inc. (AXGN) Hits New 52-Week High at $18.90

AxoGen, Inc. (NASDAQ:AXGN) hit a new 52-week high on Monday . The company traded as high as $18.90 and last traded at $18.90, with a volume of 371,590 shares trading hands. The stock had previously closed at $18.50.

A number of brokerages recently weighed in on AXGN. Roth Capital reaffirmed a “buy” rating and issued a $21.00 target price (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 target price on shares of AxoGen in a research note on Monday, August 21st. Leerink Swann began coverage on shares of AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 target price on the stock. Finally, ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. AxoGen currently has a consensus rating of “Buy” and a consensus price target of $17.20.

The company’s 50-day moving average price is $16.39 and its 200 day moving average price is $14.01. The firm’s market cap is $628.24 million.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $14.40 million. During the same period in the prior year, the firm earned ($0.09) EPS. The company’s revenue for the quarter was up 46.2% on a year-over-year basis. On average, equities analysts predict that AxoGen, Inc. will post ($0.31) EPS for the current fiscal year.

In other AxoGen news, Director Robert James Rudelius sold 16,143 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $18.00, for a total value of $290,574.00. Following the transaction, the director now owns 43,273 shares of the company’s stock, valued at approximately $778,914. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.33% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Thompson Davis & CO. Inc. grew its position in AxoGen by 575.0% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock valued at $113,000 after acquiring an additional 5,750 shares during the last quarter. Bank of America Corp DE grew its position in AxoGen by 8.7% in the 1st quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after acquiring an additional 814 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in AxoGen by 0.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after acquiring an additional 93 shares during the last quarter. TFS Capital LLC bought a new position in AxoGen in the 1st quarter valued at $120,000. Finally, Neuberger Berman Group LLC bought a new position in AxoGen in the 2nd quarter valued at $201,000. 66.77% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2017/09/18/axogen-inc-axgn-hits-new-52-week-high-at-18-90.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply